Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic or cytologic confirmation of head and neck malignancy without clinical or radiographic evidence of metastatic disease~* Locally advanced HN SCC, stages III, IV, and bulky (\> 27 cm\^3 volume) stage II, excluding larynx and nasopharynx, of no more than 150 cm\^3 volume base on CT scan~* All patients must be informed of the investigational nature of this study and must give written informed consent in accordance with institutional and federal guidelines~* Candidate for chemotherapy~* Zubrod performance score of 0 or 1~* Absolute granulocyte count (AGC) \>= 2000 cells/mm\^3~* Platelet count \>= 100,000 cells/mm\^3~* Hemoglobin \> 8.0 g/dl based upon CBC/differential obtained within 2 weeks prior to registration on study~* Serum creatinine =\< 1.5 mg/dl or measured or calculated creatinine clearance \>= 50 ml/min~* Negative pregnancy test within 2 weeks prior to registration for women of childbearing potential~Exclusion Criteria:~* Prior invasive malignancy except non-melanomatous skin cancers unless patient has been disease free for at least 3 years~* Prior cancer treatment for this cancer, including gross total tumor excision~* Prior radiation treatment to the HN region~* Patients with known syndromes that alter radiosensitivity~* Any medical contraindications for chemotherapy~* Pregnant or lactating women~* Women (of childbearing potential) and men who are sexually active and are not willing/able to use a medically acceptable form of contraception throughout the treatment and 60 days thereafter

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients undergo intensity-modulated image-guided adaptive radiotherapy once daily 5 days a week for 6 weeks. Patients also receive cisplatin IV on days 1 and 22. Treatment continues in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).